| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Proteins p53 and p73 act as transcription factors in cell cycle control, regulation of cell development and/or in apoptotic pathways. Both proteins bind to response elements (p53 DNA-binding sites), typically consisting of two copies of a motif RRRCWWGYYY. It has been demonstrated previously that DNA modification with the antitumor drug cisplatin inhibits p53 binding to a synthetic p53 DNA-binding site. Here we demonstrate that the effects of global DNA modification with cisplatin on binding of the p53 or p73 proteins to various p53 DNA-binding sites differed significantly, depending on the nucleotide sequence of the given target site. The relative sensitivities of protein-DNA binding to cisplatin DNA treatment correlated with the occurrence of sequence motifs forming stable bifunctional adducts with the drug within the target sites. Binding of both proteins to mutated p53 DNA-binding sites from which these motifs had been eliminated was only negligibly affected by cisplatin treatment.
- Proteins p53 and p73 act as transcription factors in cell cycle control, regulation of cell development and/or in apoptotic pathways. Both proteins bind to response elements (p53 DNA-binding sites), typically consisting of two copies of a motif RRRCWWGYYY. It has been demonstrated previously that DNA modification with the antitumor drug cisplatin inhibits p53 binding to a synthetic p53 DNA-binding site. Here we demonstrate that the effects of global DNA modification with cisplatin on binding of the p53 or p73 proteins to various p53 DNA-binding sites differed significantly, depending on the nucleotide sequence of the given target site. The relative sensitivities of protein-DNA binding to cisplatin DNA treatment correlated with the occurrence of sequence motifs forming stable bifunctional adducts with the drug within the target sites. Binding of both proteins to mutated p53 DNA-binding sites from which these motifs had been eliminated was only negligibly affected by cisplatin treatment. (en)
- Proteiny p53 a p53 fungují jako transkripční faktory v kontrole buněčného cyklu, regulaci buněčného vývoje a/nebo v indukci apoptózy. Oba proteiny se váží na vazebná místa (p53 DNA-vazebná místa) která se obvykle skládají ze dvou kopií motivu RRRCWWGYYY. Bylo ukázáno, že modifikace DNA protinádorovým léčivem cisplatinou inhibuje vazbu p53 na syntetická DNA vezabná místa. V této práci ukazujeme, že efekt globální modifikace cisplatinou na vazbu p53 a p73 na různá vazebná místa se velmi liší v závislosti na nukleotidové sekvenci. Relativní citlivosti vazby DNA-protein na cisplatinou modifikovanou DNA korelují s přítomností sekvenčních motivů ve vazebných místech. tvořících bifunkční adukty s léčivem. Modifikace cisplatinou DNA, ze které byly tyto sekvenční motivy odstraněny pak ovlivnila vazbu p53 i p73 jen zanedbatelně. (cs)
|
| Title
| - DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 in the target site-dependent manner
- DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 in the target site-dependent manner (en)
- Modifikace DNA cisplatinou ovlivňuje sekvenčně specifickou vazbu proteinů p53 a p73v závislosti na cílovém místě (cs)
|
| skos:prefLabel
| - DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 in the target site-dependent manner
- DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 in the target site-dependent manner (en)
- Modifikace DNA cisplatinou ovlivňuje sekvenčně specifickou vazbu proteinů p53 a p73v závislosti na cílovém místě (cs)
|
| skos:notation
| - RIV/61988987:17310/06:A0900HEA!RIV09-AV0-17310___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61988987:17310/06:A0900HEA
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - cisplatin; DNA damage; protein p73; sequence-specific DNA recognition; tumor suppressor protein p53 (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Fojta, Miroslav
- Pivoňková, Hana
- Pečinka, Petr
- Češková, Pavla
|
| http://linked.open...ain/vavai/riv/wos
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
| is http://linked.open...avai/riv/vysledek
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)